October 26, 2026

FDA expands weekly insulin use to children

Insulin icodec-abae offers a weekly basal insulin option for pediatric type 2 diabetes, supported by adult trials and pediatric pharmacokinetic data.

MDSpire News

October 22, 2026

Medical Oddities: When puberty arrives at 4 months old

A genetic mystery, hearts in space, midnight munchies, and tea with muscle power are in the lineup this week.

MDSpire News

September 01, 2026

Glycemic variability may signal retinal changes

Greater glucose fluctuations but not HbA1c were associated with neuroretinal alterations over 3 years in pediatric patients with type 1 diabetes.

MDSpire News

August 28, 2026

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

August 27, 2026

10 states that support physician work-life balance

These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.

MDSpire News

August 26, 2026

FDA authorizes continuous ketone monitor

Patients aged 2 years and older with diabetes are eligible to use the wearable.

MDSpire News

August 20, 2026

FDA approves therapy for GSDIa

The one-time gene therapy is intended to restore the deficient enzyme needed to release stored glucose during fasting.

MDSpire News

August 13, 2026

Can GH therapy improve final height after HCT?

Growth gains continued beyond the first year of treatment, while irradiation and other transplant-related factors influenced response.

MDSpire News

August 10, 2026

HHS Proposes Mandatory GRAS Notices

Manufacturers would be required to notify the FDA of GRAS determinations under a proposed rule, while HHS and USDA also submitted the first proposed federal definition of ultra-processed foods for final review.

MDSpire News

July 23, 2026

New Data for Acquired Hypothalamic Obesity

Researchers found greater reductions in body mass index and participant-reported hunger scores with setmelanotide than with placebo, although adverse and serious adverse events were more frequent in the setmelanotide group; only one serious adverse event was considered treatment-related.

MDSpire News